ARCT-810 generally safe and well tolerated, demonstrating encouraging activity across key urea cycle biomarkers in ongoing ...
While artificial intelligence can help biotech and pharma companies more quickly vet job applicants, it can also turn off the ...
ERZOFRI® is a LAI with the highest available initiation dose of paliperidone palmitate to simplify treatment initiation for ...
Tech darling Enveda has raised a total of $845 million in the past six years. The latest funding round is intended to pave ...
NAPLES, Fla.-- (BUSINESS WIRE)--Catalyst OrthoScience, Inc. ("Catalyst"), a private medical technology company elevating ...
After imeroprubart failed to demonstrate sufficient efficacy in lupus during a Phase 2b trial, Immunovant is moving on from ...
Transform-HTN (NCT05968430) is a global open-label extension trial designed to assess the safety, efficacy and tolerability ...
In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A ...
Lyrfigtu demonstrated a confirmed ORR of 46% and mDOR of 11.8 months, with a predictable and manageable safety profile FORT ...
Biotechs that announced series B financing this year and are expanding their workforces include one that raised $2.1 billion and has partnerships with Eli Lilly, Johnson & Johnson and Novartis.
EVO301 is a long-acting, native IL-18 binding protein (IL-18BP) fused to a serum albumin binding Fab, designed to neutralize ...
Mr. Cumbo brings deep experience commercializing new medicines for people with rare genetic diseases– –Company announces ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results